<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="373024">
  <stage>Registered</stage>
  <submitdate>29/05/2017</submitdate>
  <approvaldate>8/06/2017</approvaldate>
  <actrnumber>ACTRN12617000852358</actrnumber>
  <trial_identification>
    <studytitle>Near-Infrared spectroscopy for Monitoring brain Oxygenation in Premature infants </studytitle>
    <scientifictitle>Cerebral regional oxygenation and neurological outcomes in premature infants </scientifictitle>
    <utrn>U1111-1196-8545</utrn>
    <trialacronym>NIMO-Prem</trialacronym>
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cerebral regional oxygenation </healthcondition>
    <healthcondition>Prematurity </healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Complications of newborn</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Informed parental consent will be obtained in all cases prior to data collection. Once the parental consent is obtained, following data will be collected as part of the study. 

Continuous physiological measurement during the first 72hrs: 

1. Cerebral regional oxygenation (using INVOSTM 5100c/ OXYALERTTM NIRSensor Infant/Neonatal)
2. Arterial blood pressure*
3. End-tidal CO2*
4. Peripheral arterial saturation*

* These physiological measurements are part of routine clinical care in this cohort of patients.  

Non-continuous investigations:
1. Urinary biomarkers of hypoxic/ischaemic brain injury (urine will be collected non-invasively)   
2. Brain perfusion pressure (Middle Cerebral Artery Blood Flow Velocity) using Doppler ultrasound 
3. Cranial ultrasound scan (CUSS)**
4. Cardiac echocardiography**
5. MRI brain at term-equivalent age 
6. Bayley Infants Neurodevelopmental Scales**

** These investigations are part of routine clinical care in this cohort of patients. However, additional CUSS may be performed for the purpose of the study. 

Patient characteristics:      
The following demographic and clinical information will be gathered as part of the study 

1. Maternal demographics 
2. Relevant maternal past medical, antenatal and perinatal history
3. Infants perinatal and postnatal history 
</interventions>
    <comparator>No control group</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Diagnosis / Prognosis</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>White matter injury on MRI brain </outcome>
      <timepoint>Term-equivalent age (TEA) </timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Intraventricular haemorrhage (IVH) / periventricular leucomalacia (PVL) seen in cranial ultrasound scan </outcome>
      <timepoint>Day 1, day 2, day 3, 1 week and 1 month of age</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Urinary biomarkers of hypoxic/ischaemic brain injury (S100B and Activin A ELISA tests) </outcome>
      <timepoint>Day 1, day 2 and day 3 of life</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Bayley Infant Neurodevelopment Scales </outcome>
      <timepoint>One assessment to be performed at approximately 18 months of age (if a formal neurodevelopmental assessment is performed as part of clinical care between 12-24 months of age then the results from this assessment will be used instead) </timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Preterm infants (&lt;30 weeks gestation) with extremely low birth weight (&lt;1000g) who are born in Wellington Regional Hospital</inclusivecriteria>
    <inclusiveminage />
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>4</inclusivemaxage>
    <inclusivemaxagetype>Hours</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Complex congenital abnormalities 
2. Known genetic abnormalities
3. Poor skin integrity
4. Significant hydrops fetalis
5. Palliation due to extreme condition at birth </exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods>POWER ANALYSIS: Using the Receiver Operating Characteristics (ROC) curve a sample size of 120 infants will be required to detect 12% difference with the Area Under the Curve (AUC) of 0.75. </statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs>Screening</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>16/06/2017</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate>30/04/2019</anticipatedenddate>
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>30/04/2021</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Wellington</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Maria Saito-Benz</primarysponsorname>
    <primarysponsoraddress>Department of Paediatrics and Child Health
University of Otago, Wellington
23A Mein Street
Newtown 6021
Wellington </primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>University of Otago, Wellington</fundingname>
      <fundingaddress>Department of Paediatrics and Child Health
University of Otago, Wellington
23A Mein Street
Newtown 6021
Wellington </fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Government body</sponsortype>
      <sponsorname>Capital and Coast District Health Board</sponsorname>
      <sponsoraddress>Clinical Trials Unit
Wellington Regional Hospital 
Riddiford street
Newtown 
Wellington 6021</sponsoraddress>
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr Max Berry </othercollaboratorname>
      <othercollaboratoraddress>Department of Paediatrics and Child Health
University of Otago, Wellington
23A Mein Street
Newtown 6021
Wellington </othercollaboratoraddress>
      <othercollaboratorcountry>New Zealand</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>A/Prof Shieak Tzeng</othercollaboratorname>
      <othercollaboratoraddress>Centre for Translational Physiology 
University of Otago, Wellington
23A Mein Street
Newtown 6021
Wellington </othercollaboratoraddress>
      <othercollaboratorcountry>New Zealand</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>One in 12 babies in New Zealand are born premature. Premature infants, especially those born less than 30 weeks gestation and/or extremely low birth weight (&lt;1000g), carry a disproportionate burden of mortality and lifelong neurodevelopmental disability when compared to their healthy term足born peers. 

For healthy brain development ensuring adequate supply of oxygenated blood to the brain is critical; however, what constitutes the 'optimal' brain perfusion and oxygen level in premature infants is currently unknown. In this observational study we will utilise portable and non足invasive equipment and radiological imaging to develop better understanding of the optimal brain perfusion and oxygenation targets to prevent mortality and later neurodevelopmental disability. 

Of note, NIMO足Prem is the New Zealand component of a two足centre international collaborative study (the other centre being Texas Children's Hospital, USA). This study protocol is only applicable to the local study based in Wellington Regional Hospital, Wellington NZ. 
</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Health and Disability Ethics Committee</ethicname>
      <ethicaddress>Ministry of Health
Freyberg Building
20 Aitken Street
PO Box 5013
Wellington 6011</ethicaddress>
      <ethicapprovaldate>29/03/2017</ethicapprovaldate>
      <hrec>16/NTA/209</hrec>
      <ethicsubmitdate>16/11/2016</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment>
    <filepath>http://www.anzctr.org.au/AnzctrAttachments/373024-NIMO-Prem protocol .pdf</filepath>
    <filepath>http://www.anzctr.org.au/AnzctrAttachments/373024-NIMO-Prem PIS .pdf</filepath>
    <filepath>http://www.anzctr.org.au/AnzctrAttachments/373024-Consent Form NIMO-Prem (amendment v1).pdf</filepath>
    <filepath>http://www.anzctr.org.au/AnzctrAttachments/373024-HDEC Letter 16NTA209_Approved FULL Application.pdf</filepath>
    <filepath>http://www.anzctr.org.au/AnzctrAttachments/373024-Locality approval.pdf</filepath>
  </attachment>
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Maria Saito-Benz</name>
      <address>Department of Paediatrics and Child Health
University of Otago, Wellington
23A Mein Street
Newtown
Wellington 6021</address>
      <phone>+64 21 570 609</phone>
      <fax />
      <email>maria.saitobenz@otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Jenny Jeffrey</name>
      <address>Department of Paediatrics and Child Health
University of Otago, Wellington
23A Mein Street
Newtown
Wellington 6021</address>
      <phone>+64 4 918 6138</phone>
      <fax />
      <email>paediatrics.uow@otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Maria Saito-Benz</name>
      <address>Department of Paediatrics and Child Health
University of Otago, Wellington
23A Mein Street
Newtown
Wellington 6021</address>
      <phone>+64 21 570 609</phone>
      <fax />
      <email>maria.saitobenz@otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Maria Saito-Benz</name>
      <address>Department of Paediatrics and Child Health
University of Otago, Wellington
23A Mein Street
Newtown
Wellington 6021</address>
      <phone>+64 21 570 609</phone>
      <fax />
      <email>maria.saitobenz@otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>